Resistance to Ibritumomab in Lymphoma
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming r
- PDF / 3,418,474 Bytes
- 161 Pages / 439.42 x 683.15 pts Page_size
- 63 Downloads / 158 Views
Makoto Hosono · Jean-François Chatal Editors
Resistance to Ibritumomab in Lymphoma
Resistance to Targeted Anti-Cancer Therapeutics Volume 18
Series Editor: Benjamin Bonavida
More information about this series at http://www.springer.com/series/11727
Makoto Hosono • Jean-François Chatal Editors
Resistance to Ibritumomab in Lymphoma
Editors Makoto Hosono Institute of Advanced Clinical Medicine Kindai University Faculty of Medicine Osaka, Japan
Jean-François Chatal GIP Arronax Nantes-Saint-Herblain, France
ISSN 2196-5501 ISSN 2196-551X (electronic) Resistance to Targeted Anti-Cancer Therapeutics ISBN 978-3-319-78237-9 ISBN 978-3-319-78238-6 (eBook) https://doi.org/10.1007/978-3-319-78238-6 Library of Congress Control Number: 2018937356 © Springer International Publishing AG, part of Springer Nature 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by the registered company Springer International Publishing AG part of Springer Nature. The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
“Resistance to Targeted Anti-Cancer Therapeutics”: Aims and Scope
Published by Springer Inc. For several decades, treatment of cancer consisted of chemotherapeutic drugs, radiation, and hormonal therapies. These treatment regimens were not tumor specific and exhibited several toxicities. During the last several years, targeted cancer therapies (molecularly targeted drugs) have been developed and consisting of immunotherapies (cell mediated and antibody), drugs, or biologicals that can block the growth and spread of cancer by interfering with surface receptors and with specific dysregulated gene products that control tumor cell growth and progression. These include several FDA-approved drugs/antibodies/inhibitors that interfere with cell growth signaling or tumor blood ves
Data Loading...
